Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04518046
Title Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mirati Therapeutics Inc.

clear cell renal cell carcinoma

Advanced Solid Tumor


Ipilimumab + MGCD516 + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.